MedPacto gets an approval of IND for TEW-7197 from US FDA
May 19, 2014EVENTSHit 1467
MedPacto has got an approval of IND for phase 1 clinical trials with patients of solid tumor from US FDA on 24th of April, 2014. MedPacto is in the preparation of a phase 1 clinical trial in 3 different sites in the USA and expects to start the first dosing of TEW-7197 in a cancer patient coming June. TEW-7197 had been invented and developed by Ewha Womans University with a government support of the Program for Disease-Based Discovery of Global New Drug Candidates. TEW-7197 had been in-licensed to MedPacto, Inc. in July of 2013 through Theragen Etex Co. and its clinical development for oncology therapeutics is supporting by National OncoVenture, National Cancer Center in Korea.
|Attachments 20160316 메드팩토_제3기정기주주총회소집공고.docx|
|Previous||MedPacto, Inc. and OncoVenture have submitted IND application to US FDA for Medpacto's oral ALK5 inhibitor, TEW-7197.|